D.E. Shaw & Co’s Blueprint Medicines BPMC Stock Holding History

D.E. Shaw & Co’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-6,600	Closed	-$846K	–	4577
2025 Q2	$846K	Hold	6,600	–	–	﹤0.01%	3345
2025 Q1	$584K	Hold	6,600	–	–	﹤0.01%	3412
2024 Q4	$576K	Sell	6,600 -7,300	-53%	-$669K	﹤0.01%	3527
2024 Q3	$1.29M	Buy	13,900 +3,300	+31%	+$328K	﹤0.01%	3081
2024 Q2	$1.14M	Buy	10,600 +3,300	+45%	+$330K	﹤0.01%	3098
2024 Q1	$692K	Hold	7,300	–	–	﹤0.01%	3316
2023 Q4	$673K	Hold	7,300	–	–	﹤0.01%	3380
2023 Q3	$367K	Buy	+7,300	New	+$390K	﹤0.01%	3538

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

D.E. Shaw & Co's BPMC Position: Q2 2025 in Review

D.E. Shaw & Co sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 388,986 shares — an estimated $40.4M sold.

D.E. Shaw & Co first reported a position in BPMC in Q2 2015 and held it in 28 quarters. The position peaked at $35.7M in Q1 2024. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

D.E. Shaw & Co reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
D.E. Shaw & Co sold 388,986 Blueprint Medicines shares in Q2 2025, an estimated $40.4M.
D.E. Shaw & Co first reported a position in Blueprint Medicines in Q2 2015 and held it in 28 quarters.
D.E. Shaw & Co's Blueprint Medicines position peaked at $35.7M in Q1 2024.
354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on D.E. Shaw & Co's 13F filing for Q2 2025, filed 14 Aug 2025.